Neurogene names Julie Jordan as CMO

New York, USA-based rare neurological disease drug developer Neurogene (Nasdaq: NGNE) has announced the appointment of Julie Jordan as its chief medical officer (CMO).

Dr Jordan brings to Neurogene over 20 years of industry and clinical expertise involving the design and execution of global clinical trials across multiple development areas, including gene therapy and central nervous system disorders. She most recently served as CMO of Homology Medicines, a clinical-stage company advancing gene therapies for the treatment of rare diseases.

Neurogene is a clinical stage genetic medicines company developing a pipeline of differentiated genetic medicines, including NGN-401 for treatment of Rett syndrome, which uses novel gene regulation technology for a potential best-in-class profile. The company went public in December, following the completion of its merger with Neoleukin Therapeutics.